Activity Overview
Acute lymphoblastic leukemia (ALL) remains a challenging hematologic malignancy, particularly in adolescent, young adult, and older patient populations, where outcomes continue to lag behind those achieved in pediatric patients. Although recent advances in targeted therapies, immunotherapies, CAR T-cell therapies, and measurable residual disease (MRD) assessment have transformed the treatment landscape, clinicians face ongoing challenges in integrating rapidly evolving evidence, individualizing treatment strategies, and managing therapy-related toxicities.
This educational initiative is a CME-certified satellite symposium that was held in conjunction with the 2026 Society of Hematologic Oncology (SOHO®) Annual Meeting in Houston, Texas. Through expert-led presentations and case-based discussions, the program provides practical guidance on incorporating emerging therapies, optimizing MRD-driven treatment decisions, and applying the latest clinical data to improve outcomes for patients with ALL.
This educational activity is an archive of the live virtual symposium held on September 10, 2026.
Target Audience
This educational activity is directed toward medical oncologists, hematologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of acute lymphoblastic leukemia (ALL).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the efficacy and safety of emerging immunotherapy, targeted therapy, and cellular therapy strategies for patients with ALL
- Individualize treatment for patients with ALL, considering disease characteristics, treatment-related factors, and patient-related factors
- Incorporate strategies to monitor, mitigate, and manage toxicities associated with emerging therapies for ALL
- Assess recent advances in MRD testing and the evolving role of MRD in treatment planning for patients with ALL
Hagop M. Kantarjian, MD
Professor, Department of Leukemia
Samsung Distinguished Leukemia Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Hagop M. Kantarjian, MD, has no relevant financial relationships with ineligible companies.
Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Elias Jabbour, MD, has no relevant financial relationships with ineligible companies.
Aaron C. Logan, MD, PhD, MPhil
Professor of Clinical Medicine
Director, Hematologic Malignancies Tissue Bank
Hematology, Blood & Marrow Transplant, and Cellular Therapy Program
University of California, San Francisco
San Francisco, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Adaptive Biotechnologies, Amgen, Cabaletta Bio, Orca, Pfizer, Takeda; Grant/Research Funding: Amgen, Autolus, Kite/Gilead, Sanofi
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.